Lykos Therapeutics Inc. Chief Executive Officer Amy Emerson stepped down weeks after US regulators rejected the company’s psychedelic drug MDMA for treatment of post-traumatic stress disorder.
Emerson, who has led Lykos since its founding in 2014, will serve as a senior adviser through the end of the year and will serve as an observer on the company’s board, according to a statement on Thursday. Michael Mullette, who has been been chief operating officer since 2022, will become interim CEO.
The Food and Drug Administration’s Aug. 9 rejection of MDMA followed an outside panel’s vote against approval where advisers said …
More at Bloomberg
